contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


syntheticmr-ab-regulatory-approval-for-aria-monitoring-strengthens-syntheticmrs-position-with-a-broader-neuroimaging-offering

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

SyntheticMR is a medical technology company that is active in the development of analysis and imaging methods. The technology is mainly used for magnetic resonance imaging (MRI) in healthcare. The technology is based on a quantification-based method that aims to increase the efficiency and quality of MRI examinations. The company was founded in 2007 and is headquartered in Linköping.

SyntheticMR

SyntheticMR AB (publ), a global leader in quantitative MRI software, today announced continued portfolio and commercial progress following its acquisition of Combinostics Oy in early 2025. The...

<div class="abstract">SyntheticMR AB (publ), a global leader in quantitative MRI software, today announced continued portfolio and commercial progress following its acquisition of Combinostics Oy in early 2025. </div>The integration has established SyntheticMR as one unified company with a broader offering and a strengthened position in the growing neurodegenerative disease imaging segment.cNeuro® cMRI has been integrated into SyntheticMR's product portfolio, expanding the company's capabilities in quantitative and AI-driven neuroimaging. Together with SyMRI®, the combined portfolio delivers comprehensive quantitative brain imaging solutions for patients with neurological disorders.Following the acquisition, SyntheticMR has obtained regulatory approval in Europe for targeted updates to cNeuro® cMRI, including functionality for the automated detection of side effects associated with disease-modifying therapies for Alzheimer's disease, known as ARIA (Amyloid-Related Imaging Abnormalities). This responds to emerging clinical needs driven by the increasing adoption of anti-amyloid therapies in Alzheimer's disease.As MRI imaging volumes rise, cNeuro® cMRI with automated ARIA detection supports clinicians by improving workflow efficiency, strengthening diagnostic confidence, and enabling faster identification of ARIA in clinical practice.In parallel, cNeuro® cMRI has been introduced in the Indian market, leveraging its established SyMRI® presence to expand in a key growth region."The acquisition of Combinostics has enabled us to operate as one stronger organization with a broader portfolio." said Lena Åredal, CEO of SyntheticMR. "By aligning expertise across the company, we are strengthening our offering and positioning SyntheticMR as a leading provider of comprehensive solutions in neurodegenerative imaging."SyntheticMR remains focused on innovation, regulatory expansion, and commercial execution to meet evolving clinical needs and drive sustainable long-term growth.&nbsp;<div></div>

SyntheticMR AB: Regulatory Approval for ARIA Monitoring Strengthens SyntheticMR's Position with a Broader Neuroimaging Offering

Faron Pharmaceuticals

Herantis Pharma

Mendus

Probabilities of success in drug development

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Solar Foods

Solar Foods is planning a listing on the Nasdaq First North Growth Market Finland marketplace

Return on capital (ROE, ROI, ROIC, RONIC)

The DuPont formula helps understand the dynamics of value creation